Follicular lymphoma, small lymphocytic lymphoma/chronic lymphocytic leukemia, mantle cell lymphoma, nodal marginal zone B cell lymphoma, MALT lymphoma, lymphoplasmacytic lymphoma, diffuse large B-cell lymphoma Cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Surface immunoglobulin G or M isotype expression on tumor cells 2. Presence of tumor tissue biopsy before any treatment 3. The physical status scale ESOG 0 - 2 4. Life expectancy at least 24 months 5. Age 18 to 75 years 6. Adequate renal, hepatic, and bone marrow function 7. Signed written informed consent 8. The patient's ability to carry out the instructions of the doctor-researcher and comply with the treatment plan
Exclusion criteria
Exclusion criteria: 1. Pregnancy and lactation 2. The presence of multiple primary cancer 3. History of autoimmune diseases (except Hashimoto's thyroiditis) 4. Severe diseases, including proceeding with symptomatic, untreated inflammatory and infectious processes 5. Social, economic or geographic circumstances which impede proper compliance with treatment protocols and follow-up 6. Polysensitisation 7. Positive tests for human immunodeficiency virus (HIV), hepatitis B or C
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety and tolerability of vaccination; local and systemic adverse events are observed and symptoms are measured according to Common Terminology Criteria for Adverse Events v4.0 (CTCAE) | — |
Secondary
| Measure | Time frame |
|---|---|
| Immunologic response to vaccination (anti-Id cellular and humoral immune response), measured using ELISPOT and ELISA at diagnosis (before treatment), before vaccination (after treatment), 1 week, 1 month and 2 months after the last vaccination | — |
Countries
Belarus